4.6 Article

Programmed death 1 is highly expressed on CD8+ CD57+ T cells in patients with stable multiple sclerosis and inhibits their cytotoxic response to Epstein-Barr virus

期刊

IMMUNOLOGY
卷 152, 期 4, 页码 660-676

出版社

WILEY
DOI: 10.1111/imm.12808

关键词

CD8(+); CD57(+) T cells; cytotoxic T-cell response; Epstein-Barr virus; multiple sclerosis; programmed death 1

资金

  1. Fondazione Italiana Sclerosi Multipla (FISM) [2013/B/2]
  2. FISM [2015/R/16, 2013/R/2]
  3. Italian Ministry of Health, Italy [RF-2011-02347228]
  4. UK Multiple Sclerosis Society

向作者/读者索取更多资源

Growing evidence points to a deregulated response to Epstein-Barr virus (EBV) in the central nervous system of patients with multiple sclerosis (MS) as a possible cause of disease. We have investigated the response of a subpopulation of effector CD8(+) T cells to EBV in 36 healthy donors and in 35 patients with MS in active and inactive disease. We have measured the expression of markers of degranulation, the release of cytokines, cytotoxicity and the regulation of effector functions by inhibitory receptors, such as programmed death 1 (PD-1) and human inhibitor receptor immunoglobulin-like transcript 2 (ILT2). We demonstrate that polyfunctional cytotoxic CD8(+)CD57(+) T cells are able to kill EBV-infected cells in healthy donors. In contrast, an anergic exhaustion-like phenotype of CD8(+)CD57(+) T cells with high expression of PD-1 was observed in inactive patients with MS compared wit active patients with MS or healthy donors. Detection of CD8(+)CD57(+) T cells in meningeal inflammatory infiltrates from post-mortem MS tissue confirmed the association of this cell phenotype with the disease pathological process. The overall results suggest that ineffective immune control of EBV in patietns with MS during remission may be one factor preceding and enabling the reactivation of the virus in the central nervous system and may cause exacerbation of the disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据